$385.56 Million 3D Bioprinting Market – Global Growth, Trends and Forecasts 2018-2019 & 2023 – ResearchAndMarkets.com

Bioprinting Market – Growth, Trends and Forecasts (2018 – 2023)”

report has been added to ResearchAndMarkets.com’s

The Global 3D Bioprinting Market was valued at USD 385.56 million in
2018 and is expected to register a CAGR of 25.36% during the forecast
period (2019-2024).

The global 3D bioprinting market is expected to grow, owing to its
revolutionary breakthrough in healthcare and pharmaceutical industries.
The increasing technological advancements, government intervention for
improving healthcare, and increasing investments in R&D are also
significant factors driving the studied market growth.

The primarily growing bioprinting applications include 3D bioprinted
tissue and hair follicles, as they are very beneficial to cosmetics
companies, especially in Europe, where animal testing for cosmetics was
banned in 2013. For a cosmetic company, the advantage will be the
ability to economically and ethically test products (i.e., not on
animals) across varying skin types, for more accurate results.

Growing government support is also attracting many investors to invest
in R&D programs, which is expected to develop space for the studied
market. In 2018, Mapp Biopharmaceutical Inc. announced that it had been
awarded a contract of USD14.8 million, with options for an additional
USD 32.0 million, by the Biomedical Advanced Research and Development
Authority (BARDA).

Further, a significant increase in the number of older adults is
projected in the coming decades, which is expected to drive the need for
3D bioprinting reflecting the growth of the market.

Scope of the Report

3D bioprinting is an emerging field represented by various biologically
applied deposition and assembling systems, which include direct writing,
photolithography, microstamping, extrusion, laser writing,
stereolithography, electro-printing, microfluidics, and inkjet

Key Market Trends

Drug Testing to Hold Major Share

3D bioprinters are of the highest importance for drug testing and
clinical trials applications expected to drastically reduce the need for
animal trials (therefore not only being ethically beneficial but also
being cost-effective).

Traditionally, clinical trials for new drug development involved testing
on animals with artificially induced affected tissues. With the advent
of 3D bioprinting, drug developers will be able to address the
complications associated with human clinical trials of new drugs, by
identifying them in a short period (since these can be tested with
human-like 3D printed tissues).

Thus, they are expected to reduce the losses incurred during late-stage
failures. The regulatory agency of the United States Food and Drug
Administration has already started to consider integrating alternatives
for drug safety and efficacy assessment, providing scope for the market.
Companies like Organovo (US based) were instrumental in the development
of 3D bioprinter able to develop liver and kidney tissue for drug
discovery applications.

Cosmetic companies are also potential buyers of the bioprinter
technology. In 2013, the European Union prohibited the use of cosmetics
developed by animal testing. Prohibition of retailing products tested
abroad on animals was also levied. Such regulations have accelerated the
use of alternatives like bioprinting.

Asia-Pacific Anticipated to Witness Fastest Growth

Asia-Pacific is the fastest growing market for 3D bioprinting, mainly
due to a strong existing consumer base that will drive demand for 3D
bioprinting, huge scope of 3D printing in medical services, increasing
R&D for 3D printing, and government support and tax incentives. The
growing number of cancer cases and the increasing the number of cancer
treatments in the region are also expected to fuel the adoption of 3D
bioprinting technology. According to the World Cancer Research Fund, the
cancer rate is the highest in Australia and New Zealand in the world.

Competitive Landscape

The 3D bioprinting market is highly competitive and consists of several
major players. In terms of market share, few of the major players
currently dominate the market. These major players with a prominent
share in the market are focusing on expanding their customer base across
foreign countries. These companies are leveraging on strategic
collaborative initiatives to increase their market share and increase
their profitability.

In Feb 2018, 3D Systems introduced NextDent 5100, a Figure 4-based 3D
bioprinter designed for dental labs. NextDent 5100 facilitates
high-speed 3D bioprinting for production of dental appliances and
sacrificial castings. Further in Dec 2018, Aspect Biosystems has made a
collaboration with the Institute for Technology-Inspired Regenerative
Medicine (MERLN) at Maastricht University in the Netherlands.

This collaboration includes the placement of an RX1 Bioprinting Platform
in Professor Lorenzo Moroni’s Lab, where it will be used to develop
kidney tissue by a head of bioprinting research, Dr. Carlos Mota. Under
the terms of the collaborative research agreement, Aspect has an option
to further develop and commercialize products based on the results of
the research.

Key Topics Covered:





4.1 Market Overview

4.2 Introduction to Market Drivers and Restraints

4.3 Market Drivers

4.3.1 Increasing Geriatric Population

4.3.2 Increasing Organ Transplant Requirements

4.3.3 Increasing Investments In R&D

4.4 Market Restraints

4.4.1 Operational Challenges

4.5 Industry Attractiveness Porter’s Five Force Analysis

4.6 Industry Value Chain Analysis


5.1 By Technology

5.1.1 Syringe/Extrusion Bioprinting

5.1.2 Inkjet Bioprinting

5.1.3 Magnetic Levitation Bioprinting

5.1.4 Laser-assisted Bioprinting

5.1.5 Other Technologies

5.2 By Component

5.2.1 3D Bioprinters

5.2.2 Biomaterials

5.2.3 Scaffolds

5.3 By Application

5.3.1 Drug Testing and Development

5.3.2 Regenerative Medicine

5.3.3 Food testing

5.3.4 Research

5.3.5 Other Applications

5.4 Geography


6.1 Company Profiles

6.1.1 3D Systems Corporation

6.1.2 Aspect Biosystems Ltd

6.1.3 GeSIM GmbH

6.1.4 Bio3D Technologies

6.1.5 Allevi Inc.

6.1.6 Cyfuse Biomedical KK

6.1.7 Envision TEC GmbH

6.1.8 Organovo Holdings Inc.

6.1.9 3Dynamic Systems Ltd

6.1.10 RegenHU SA

6.1.11 Stratasys Ltd

6.1.12 REGEMAT 3D

6.1.13 3D Bioprinting Solutions

6.1.14 Arcam AB (GE Company)



For more information about this report visit https://www.researchandmarkets.com/r/aafg0r


Laura Wood, Senior Press Manager
[email protected]
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Biomaterials

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.